The incidence of Dementia is set to triple in the next 30 years owing to population growth and longer life expectancy. The study examined 4 major risk factors: obesity, high blood sugar, smoking and level of education. Read more below.. https://www.imt.ie/clinical/global-dementia-cases-to-triple-by-2050-study-14-01-2022/ We’ve added an education update covering Dementia & Alzheimers from uptodate.com be sure to …
Ongoing Roactemra supply difficulties are set to continue as the European Medicines Agency approves its use for adults with severe COVID-19 who are in receipt of systemic treatment with corticosteroids and requiring supplemental oxygen or mechanical ventilation. Read more below.. RoActemra (tocilizumab) approved by EMA for use in severe COVID-19
Oral anti-Covid treatments have been developed and licenced for use – Lagevrio and Paxlovid. Dr JJ Keating and Dr Tim O’Sullivan from the UCC School of Pharmacy explain everything in this article. https://www.rte.ie/brainstorm/2021/1207/1265254-covid-19-antiviral-drugs-pfizer-merck-lagevrio-paxlovid-molnupiravir-ritonavir/ SPC link for Lagevrio: https://www.medicines.org.uk/emc/product/13044/smpc#gref
Data published in The Lancet has found that the risk of having COVID symptoms for 28 days or more after post-vaccination infection were approximately halved. Read more below.. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00460-6/fulltext#seccestitle150
